AzTrials
AzTrials

Advanced Biliary Tract TumorsPhase 2NCT04191343

Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

A Phase 2 study testing Toripalimab injection combined with GEMOX in people with Advanced Biliary Tract Tumors, run by Zhejiang Cancer Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is an open, single-arm, single-center, prospective phase II clinical study to evaluate the efficacy and safety of first-line tripletrumab combined with GEMOX chemotherapy in patients with advanced biliary tract tumors. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Advanced Biliary Tract Tumors
What is being tested?
Toripalimab injection combined with GEMOX
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteChina
Study dates
14 Oct 2019to Jun 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 and ≤75.
  • KPS score ≥80 points within 7 days before inclusion.
  • For subjects with previously untreated advanced or metastatic biliary tract systemic tumors (gallbladder cancer, intrahepatic and extrahepatic cholangiocarcinoma), or who have previously undergone radical surgery + adjuvant therapy, the metastatic lesions should be detected for the first time at ≥6 months after the last adjuvant treatment, and the pathological type is adenocarcinoma.
  • In CT/MRI examination, there was at least one measurable lesion according to RECIST1.1 criteria.
  • The blood routine and biochemical indicators of the subject within 7 days before enrollment meet the following standards:
  • Hemoglobin ≥90g/L; Absolute count of neutrophils (ANC) ≥1.5×109/L; Platelet ≥100×109/L (patients should not receive blood transfusion or growth factor support within 14 days after blood collection);
Show all 15Show fewer
  • ALT and AST≤2.5 times normal upper limit (ULN); ALP 2.5 x ULN or less;
  • Total bilirubin <1.5 ULN (patients with Gilbert syndrome can be included if total bilirubin <3 ULN);
  • Serum creatinine <1.5 ULN or estimated glomerular filtration rate ≥60ml/min/1.73m2 (appendix 3);
  • Serum albumin≥30g/L;
  • International standardized ratio (INR) or prothrombin time (PT) ≤1.5 ULN, unless the patient is receiving anticoagulant therapy and PT is within the anticoagulant expected treatment range;
  • Activated partial thromboplastin time (APTT) ≤1.5 times ULN.
  • Be able to follow the protocol during the study period. 7) provide written informed consent before entering the study, and patients have been informed that they can withdraw from the study at any time without any loss.
  • Fertile women (appendix 6) must test negative for urine or serum pregnancy within 7 days prior to enrollment and must agree to use effective contraception for at least 120 days during the study period and after the last administration (including chemotherapy and triplegizumab).
  • Unsterilized men must agree to use effective contraception during the study period and for at least 120 days after their last dose.

Who cannot join

  • Previous treatment for biliary tract tumors, including radiotherapy, chemotherapy and immunotherapy (except for patients with recurrence more than 6 months after the end of previous adjuvant therapy)
  • Patients with active autoimmune diseases or a history of autoimmune diseases that may recur . Note: patients with the following diseases are not excluded and can be further screened:
  • controlled type 1 diabetes
  • hypothyroidism (which can be controlled with hormone replacement therapy alone)
  • controlled celiac disease
  • skin diseases that require no systemic treatment (e.g. Vitiligo, psoriasis, alopecia)
Show all 38Show fewer
  • Any other disease that is not expected to recur in the absence of an external trigger
  • Any active malignancy within 2 years, except for specific cancers being studied in this trial and locally recurrent cancers that have been cured (such as excised basal or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ).
  • There was uncontrollable pleural effusion, pericardial effusion or ascites requiring frequent drainage within 14 days prior to enrollment (cytological examination of effusion was allowed).
  • Patients with gastrointestinal bleeding within the first two weeks of inclusion, or those with high blood risk as judged by the researchers.
  • Gastrointestinal perforation and/or fistula occurred within 6 months before admission.
  • Body weight loss≥20% in the first 2 months.
  • Lung diseases of clinical significance: interstitial pulmonary disease, non-infectious pneumonia, pulmonary fibrosis, acute pulmonary disease, etc.
  • Uncontrollable systemic diseases including diabetes, hypertension, etc.
  • Severe chronic or active infections, including tuberculosis and HIV infection, that require systemic antibacterial, antifungal or antiviral treatment.
  • Untreated chronic hepatitis b or chronic HBV carriers with hepatitis b virus (HBV) DNA exceeding 1000 IU/mL, or hepatitis c virus (HCV) RNA positive patients should be excluded. Nonactive hepatitis b surface resistance Original (HBsAg) carriers, treated and stable hepatitis b patients (HBV DNA <1000IU/mL), and cured hepatitis c patients may be included.
  • Any of the following cardiovascular risk factors:
  • The occurrence of cardiogenic chest pain within no more than 28 days before enrollment was defined as moderate pain with limited daily living activities.
  • Symptomatic pulmonary embolism occurred within 28 days or less before enrollment.
  • Acute myocardial infarction occurred within less than 6 months before inclusion.
  • Any history of heart failure reaching the New York heart association level III/IV (appendix 5) less than 6 months prior to enrollment.
  • Ventricular arrhythmias of grade 2 or greater occurred within less than 6 months before inclusion, or were accompanied by supraventricular tachyarrhythmias requiring drug treatment.
  • Cerebrovascular accident (CVA) occurred within less than 6 months before inclusion.
  • Peripheral nerve disease is known to exceed NCI-CTCAE level 1. CTCAE 1However, patients with only deep tendon reflex (DTR) disappearance need not be excluded.
  • Moderate or severe renal impairment [creatinine resolution equal to or less than 50 ml/min (based on the Cockroft and Gault equations)], or serum creatinine > normal upper limit (ULN).
  • Allergic to any component of the study drug.
  • Have undergone allogeneic stem cell transplantation or organ transplantation.
  • Corticosteroids (prednisone with a dose higher than 10 mg/d or similar drugs) should be used within 14 days before enrollment Isodose) or other immunosuppressant systemic therapy. Note: patients who currently or previously used any of the following steroid regimens may be included:
  • Adrenalin alternative steroids (prednisone≤10mg/d or equivalent)
  • Topical, intraocular, intraarticular, intranasal and inhaled corticosteroids with minimal systemic absorption.
  • Short-term (≤7 days) use of corticosteroids for prophylaxis (e.g Antiemetic agents for specific chemotherapy) or for the treatment of non-autoimmune conditions (such as delayed hypersensitivity caused by exposure to allergens).
  • Received live vaccine within 4 weeks prior to enrollment. (note: seasonal influenza vaccines are usually inactivated vaccines and are permitted. Vaccines used in the nasal cavity are live vaccines and should not be used.
  • Received: immunotherapy within 28 days prior to enrollment or within 5 half-lives (whichever is shorter, but at least 14 days) Treatment (such as interleukin, interferon, thymosin, etc.) or any experimental treatment.
  • Palliative radiotherapy was given within 14 days prior to enrollment.
  • Have received anti-pd-1, anti-pd-l1, anti-pd-l2 or any other specific targeted t-cell co-stimulation or checkpoint pathway antibody or drug therapy.
  • Receive major surgery within 28 days prior to enrollment, unless the surgery is minimally invasive (e.g., central venous catheterization through peripheral venipuncture [PICC]).
  • In the case of uncontrolled epilepsy, CNS disease or mental disorder, the investigator shall determine whether the clinical severity interferes with the signing of the informed consent or affects the patient's oral medication compliance.
  • There are potential medical conditions or alcohol/drug abuse or dependence that researchers consider to be detrimental to the study of drug administration or to the interpretation of drug toxicity or adverse events.

Trial locations and contacts

1 site in 1 country.

Zhong H Jun, Master contact

13957101712

Yuanmq@zjcc.org.cn

China1 site, 1 recruiting

  • Haijun Zhong

    Zhenjiang, Hangzhou, 310000

    Zhong H Jun, Master, 13957101712, Yuanmq@zjcc.org.cn

    Recruiting

Other trials in China

About this study

Official title: A Single-arm, Single-center, Prospective Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

This is an open, single-arm, single-center, prospective phase II clinical study to evaluate the efficacy and safety of first-line tripletrumab combined with GEMOX chemotherapy in patients with advanced biliary tract tumors.

Selected patients will receive the following treatment:

Triplel monoclonal antibody (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w) until the disease progresses or an intolerable adverse reaction occurs (the maximum treatment time is 2 years).

Being tested
Toripalimab injection combined with GEMOX

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Toripalimab injection combined with GEMOXDrug

    Toripalimab Injection (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w)

Study groups in NCT04191343
Study groupRoleWhat they receive
The control groupExperimentalNot described
Receives: Drug: Toripalimab injection combined with GEMOX

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective response rate(ORR)

    Objective response rate (ORR) on imaging of Toripalimab combined with chemotherapy

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2019
  2. Study start14 Oct 2019
  3. Primary completionSep 2023 (estimated)
  4. Study completionJun 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04191343
Sponsor's protocol ID
IRB-2019-91
Status last verified
Dec 2019
First submitted
6 Dec 2019
Last updated
9 Dec 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Toripalimab injection combined with GEMOX in people with Advanced Biliary Tract Tumors, run by Zhejiang Cancer Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Zhong H Jun, Master (13957101712, Yuanmq@zjcc.org.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective response rate(ORR) (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04191343.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in